Neoadjuvant CRT plus sintilimab yielded a higher pCR rate than neoadjuvant chemo plus sintilimab in patients with locally advanced ESCC.
I call it cancer — the cancer caused by the Biden administration,” Trump told reporters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback